Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

por Torkildsen G, Narvekar A, Bergmann M
Publicado 2015

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects

por Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC
Publicado 2019

Safety and comfort evaluation of a new formulation of Visine® lubricant eye drops containing HydroBlend™ and GentlePur™

por Torkildsen G, Frisch S, Bai M, Gentner III L, Doshi U, Zhang J
Publicado 2016

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial

por Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd
Publicado 2011

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis

por McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G
Publicado 2017

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye

por Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, Lama T, Cumberlidge G, Ousler GW III
Publicado 2013

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye

por Torkildsen G, Brujic M, Cooper MS, Karpecki P, Majmudar P, Trattler W, Reis M, Ciolino JB
Publicado 2017

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

por Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, Duggal A
Publicado 2019